Gut Microbiome in Chronic Kidney Disease

Página do item simplificado
dc.citation.issue4
dc.citation.volume19
dc.contributor.authorArmani, R. G. [UNIFESP]
dc.contributor.authorRamezani, A.
dc.contributor.authorYasir, A.
dc.contributor.authorSharama, S.
dc.contributor.authorCanziani, M. E. F. [UNIFESP]
dc.contributor.authorRaj, D. S.
dc.coverageNew York
dc.date.accessioned2020-07-17T14:02:33Z
dc.date.available2020-07-17T14:02:33Z
dc.date.issued2017
dc.description.abstractWith over 100 trillion microbial cells, the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. Gut microbiome dysbiosis, resulted from alteration of composition and function of the gut microbiome and disruption of gut barrier function, is commonly seen in patients with chronic kidney disease (CKD). The dysbiotic gut microbiome generates excessive amounts of uremic toxins, and the impaired intestinal barrier permits translocation of these toxins into the systemic circulation. Many of these uremic toxins have been implicated in the progression of CKD and increased cardiovascular risk. Various therapeutic interventions have been proposed that aim to restore gut microbiome symbiosis. If proven effective, these interventions will have a significant impact on the management of CKD patients. In this review, we discuss the consequences of gut microbiome dysbiosis in the context of CKD, discuss the consequences of gut dysbiosis, and highlight some of the recent interventions targeting the gut microbiome for therapeutic purposes.en
dc.description.affiliationUniv Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazil
dc.description.affiliationGeorge Washington Univ, Sch Med, Div Renal Dis & Hypertens, 2150 Penn Ave NW, Washington, DC 20037 USA
dc.description.affiliationUnifespUniv Fed Sao Paulo, Dept Med, Div Nephrol, Sao Paulo, Brazi
dc.description.sourceWeb of Science
dc.description.sponsorshipNational Institutes of Health grant
dc.description.sponsorshipIDNational Institutes of Health grant: 1R01DK073665-01A1
dc.description.sponsorshipIDNational Institutes of Health grant: 1U01DK099924-01
dc.description.sponsorshipIDNational Institutes of Health grant: 1U01DK099914-01
dc.format.extent-
dc.identifierhttp://dx.doi.org/10.1007/s11906-017-0727-0
dc.identifier.citationCurrent Hypertension Reports. New York, v. 19, n. 4, p. -, 2017.
dc.identifier.doi10.1007/s11906-017-0727-0
dc.identifier.issn1522-6417
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54861
dc.identifier.wosWOS:000397929900006
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofCurrent Hypertension Reports
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectMicrobiomeen
dc.subjectDysbiosisen
dc.subjectUremic toxinen
dc.subjectChronic kidney diseaseen
dc.subjectCardiovascular diseaseen
dc.titleGut Microbiome in Chronic Kidney Diseaseen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos